BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CGT4255 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CGT4255\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07361562-2426@assetmemo.bio
DTSTAMP:20261121T005607Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:CGT4255: Phase 1 readout est. (NCT07361562)
DESCRIPTION:CGT4255\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Study
  of a Selective ERBB2 Inhibitor (CGT4255)\, in Patients With Advanced Soli
 d Tumors\nEstimated primary completion: May 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/cgt4255#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07361562
URL:https://assetmemo.bio/drug/cgt4255#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
